In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MGI Pharma Inc.

Division of Eisai Co. Ltd.
www.mgipharma.com

Latest From MGI Pharma Inc.

Eisai's New Venture Fund Looks To ‘Excavate’ Innovation

Japanese pharma firm’s new venture capital fund aims to support and gain access to external innovation both at home and in the US, while a new alliance with a Japanese tech services firm will pursue opportunities in digital health and dementia.

Japan Financing

Sale of Invention May Block Its Patenting Even If Details Are Not Disclosed, Supreme Court Concludes

America Invents Act did not alter the meaning of "on sale," unanimous court finds, so a confidential sale can qualify as prior art.

Legal Issues Intellectual Property

Brand Vs. Generic Supreme Court Fight: Does Sale Of Secret Invention Bar Its Patenting?

In case with potentially broad ramifications for biopharma partnerships, high court will hear arguments Dec. 4 on whether America Invents Act changed the "on-sale bar" to patentability to allow inventions that are sold to be patented if their details are not publicly disclosed.

Legal Issues Intellectual Property

Eisai Offloads AkaRx To Tighten Therapeutic Focus

Eisai is divesting its AkaRx operation and assets, acquired in 2010, to a health care-focused US private equity group in a move the Japanese firm says will free up resources for its two main therapeutic areas.

BioPharmaceutical Japan
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register